A genetic study has been performed on five adrenoleucodystrophy families using DNA probes from Xq28. Members of each family had previously been tested for carrier status using the biochemical assay for very long chain fatty acids (VLCFAs), but several persons at risk had equivocal results. DNA analysis with four DNA probes Stl4-1 (DXS52), DX13 (DXSI5), MN12 (DXS33), and hs7 showed no crossovers between them and the disease locus in persons who were clinicaily affected or had high levels of VLCFA or both. Thus, the genotypes provided by the DNA probes could be used for accurate carrier detection and prenatal diagnosis could be offered. Of the 17 at risk females with VLCFA levels in the normal ( In order to improve the detection of carriers, linkage to DNA markers has been sought. The highly polymorphic DNA probe St14-1 has been shown to be tightly linked to and has been used in ALD families to supplement the biochemical assay.8 The DNA probe hs7 which detects the red-green pigment genes is also found to be tightly linked to ALD.9 In this study we present DNA analysis with St 14-1 on five ALD families. These data are used to improve the assignment of carrier status for persons with equivocal VLCFA levels. Further DNA probes from Xq28 (MN12, DX13, and hs7) have been used in an attempt to determine an order with respect to the ALD gene, and to extend the scope of carrier detection and prenatal diagnosis.
acid, C24:0) by adding an acyl-CoA. 4 This activation of the fatty acid is the first step of five in the peroxisomal beta oxidation system. It is here that the accumulation of VLCFAs occurs owing to the impairment of this enzyme. The gene responsible for this disease has not been isolated, but close linkage with G6PD has assigned the genetic defect responsible for ALD to Xq28. 5 Biochemical methods for determining carrier status consist of assaying hexacosanoic acid (C26:0) in plasma and cultured fibroblasts, and comparing this level to that of other very long chain fatty acids. In this way up to 93% of obligatory heterozygotes can be identified, the remaining 7% having results in the normal range.6 By making allowance for this overlap between obligatory heterozygotes and normals, Moser et at6 concluded that about 77% of mothers of isolated cases were carriers. However, because of uncertainty in advising individual women, Moser et at6 suggested that women at high pedigree risk of being carriers should be offered prenatal diagnosis of ALD, as measurement of VLCFA on cultured amniotic and chorionic cells is a reliable diagnostic test for affected males.
In order to improve the detection of carriers, linkage to DNA markers has been sought. The highly polymorphic DNA probe St14-1 has been shown to be tightly linked to ALD (Zmax= 19-10 at H=0-007) and has been used in ALD families to supplement the biochemical assay.8 The DNA probe hs7 which detects the red-green pigment genes is also found to be tightly linked to ALD.9 In this study we present DNA analysis with St 14-1 on five ALD families. These 
Discussion
The published lod score of ALD against St14-1 was obtained by using the VLCFA measurements to determine the carrier status of individual subjects.8 18 Using the same approach in these families, the lod score (using the LIPED program) for Stl4-1 against ALD was Zmax=5-37, 0=0.00 (confidence limits 0-00 to 0-09). These results increase the lod score to Zmax=24-47, 0=0-00.
As no crossovers were observed between the probes used and ALD, the order of the probes with respect to the disease gene is still unknown. As MN12, St14-1, and DX1 3 are closely linked to one another, " I then in the rare case where Stl4-l is uninformative (family D), DX13 and MN12 can be used. The Sacl polymorphism detected by hs7 was not very informative in our families. The only time the Sacl polymorphism was used with certainty was in family B where the allele B2 (18 kb), which was segregating with ALD, could be clearly distinguished. Therefore this family could be typed clearly with hs7, and IV 6, who was only informative with this probe, could be offered prenatal diagnosis.
The percentage of heterozygotes that can be detected by VLCFA measurements varies from 80 to 93% according to whether levels in plasma are measured, or whether levels in cultured fibroblasts are also examined.6 1719 In our families, plasma specimens were sent to Dr Moser in Baltimore and normal results were not followed with skin biopsies. Unfortunately, only one of the four obligatory nonmanifesting heterozygotes had a C26:0 level above 1 SD from the control mean. This meant that the 17 at risk females in these families with normal VLCFA levels could not be reassured; two further at risk females had clearly high levels (IV-6 in family B and II-7 in family E). As DNA studies showed no crossovers between the DNA probes St14-1, MN12, DX13, hs7 and unequivocal disease status in these families, we could use their inheritance patterns to determine the carrier status of all but six of the 17 possible carriers. The six who could not be firmly categorised were the mothers, aunts, and sisters of the isolated case in family C, although risks could be assigned to them with a high degree of probability.
Of the 25 mothers, aunts, and sisters of index patients, two were manifesting carriers, five were obligatory heterozygotes (which included one of the manifesting carriers), two had high levels of plasma VLCFA but no neurological manifestations, two were carriers because of their Stl4-1 genotype but had normal VLCFA levels, 12 were considered not to be carriers because of their genotype and normal VLCFA levels, and three were assigned risks based on pedigree analysis and the finding of normal VLCFA levels (all from family C). Therefore, in the families with multiple cases, DNA analysis could define carrier status in all the at risk females who had VLCFA levels in the normal range and was useful in the one family with an isolated case. All the carrier females could be offered prenatal diagnosis using the DNA probes.
Further experience of the combined use of VLCFA measurements and DNA analysis will lead to more precise risks being calculated for those relatives of isolated cases who have levels in the high normal range. For example, in this study, two of four possible carriers with C26:0 levels between the mean and 1 SD were identified as a carrier through DNA analysis, and no woman with a C26:0 below the control mean was considered to be a carrier as a result of DNA analysis.
In this molecular genetic study, spastic paraparesis, ALD, and AMN were segregating together. The major defect in this kind of neurological disease may be the result of a mutation in a gene at Xq28, but the complexity of the disease suggests that other genes or secondary effects or both could account for the variety of manifestations.
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